Thrombosis and Haemostasis, Inhaltsverzeichnis Thromb Haemost 2005; 93(01): 106-114DOI: 10.1160/TH04-06-0340 Platelets and Blood Cells Schattauer GmbH RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system Anirban Sen Gupta 1 Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA , Guofeng Huang 1 Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA , Brian J. Lestini 1 Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA , Sharon Sagnella 1 Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA , Kandice Kottke-Marchant 2 Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, USA , Roger E. Marchant 1 Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA › Institutsangaben Artikel empfehlen Abstract Volltext als PDF herunterladen Keywords KeywordsLiposomes - RGD-modification - platelet-targeted - drug delivery Referenzen References 1 Fishbein I, Waltenberger J, Banai S. et al Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats. Arterioscler Thromb Vasc Biol 2000; 20: 667-76. 2 Kandarpa K, Nakatsuka S, Bravo SM. et al Mural delivery of iloprost with use of hydrogel-coated balloon catheters suppresses local platelet aggregation. J Vasc Interv Radiol 1997; 8: 997-1004. 3 Nugent HM, Edelman ER. Local drug delivery and tissue engineering regulate vascular injury. Curr Pharm Des 1997; 3: 529-44. 4 Mauro L, Borovicka M, Kline S. Introduction to coronary artery stents and their pharmacotherapeutic management. Ann Pharmacother 1997; 31: 1490-8. 5 Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 1996; 28: 1643-51. 6 Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE and EPILOG trials into perspective. Am J Cardiol 1996; 78: 35-40. 7 Jang Y, Lincoff A, Plow EF. et al Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994; 24: 1591-601. 8 Barron M, Lake R, Buda A. et al Intimal hyperplasia after balloon injury is attenuated by blocking selectins. Circulation 1997; 96: 3587-92. 9 D'Souza SE, Ginsberg MH, Natsueda GR. et al A discrete sequence in a platelet integrin is involved in ligand recognition. Nature 1991; 350: 66-68. 10 Cierniewski CS, Byzova T, Papierak M. et al Peptide ligands can bind to distinct sites in Integrin aIIbß 3 and elicit different functional responses. J Biol Chem 1999; 274: 16923-32. 11 Deckmyn H, Ulrichts H, Van de Walle G. et al Platelet antigens and their function. Vox Sanguinis 2004; 87: S105-S111. 12 Pytela R, Piersbacher MD, Ginsberg MH. et al Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986; 231: 1559-62. 13 Lam SC-T, Plow EF, Smith MA. et al Evidence that arginyl-glycyl-aspartate peptides share a common binding site on platelets. J Biol Chem 1987; 262: 947-50. 14 Gyongyossy-Issa I M, Muller W, Devine DV. The covalent coupling of Arg-Gly-Asp-containing peptides to liposomes: purification and biochemical function of the lipopeptide. Arch Biochem Biophys 1998; 353: 101-8. 15 Nishiya T, Sloan S. Interaction of RGD liposomes with platelets. Biochem Biophys Res Commun 1996; 224: 242-5. 16 Berndt P, Fields GB, Tirrell M. Synthetic lipidation of peptides and amino acids: monolayer structure and properties. J Am Chem Soc 1995; 117: 9515-22. 17 Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int Journal Peptide Protein Res 1990; 35: 161-214. 18 Plow E, Pierschbacher M, Ruoslahti E. et al Arginyl- glycyl-aspartic acid sequences and fibrinogen binding to platelets. Blood 1987; 70: 110-15. 19 D'Souza SE, Haas TA, Piotrowicz RS. et al Ligand and cation binding are dual functions of a discrete segment of the integrin b3 subunit: cation displacement is involved in ligand binding. Cell 1994; 79: 659-67. 20 Lestini BJ, Sagnella SM, XY Z. et al Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J. Control Rel 2002; 78: 235-47. 21 Michelson AD. Flow cytometry: A clinical test of platelet function. Blood 1996; 87: 4925-36. 22 Schmitz G, Rothe G, Ruf A. et al European working group on clinical cell analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998; 79: 885-96. 23 Craig WS, Cheng S, Mullen DG. et al Concept and progress in the development of RGD-containing peptide pharmaceuticals. Biopolymers (Peptide Science) 1995; 37: 157-75. 24 Beer JH, Springer KT, Coller BS. Immobilized Arg-Gly-Asp (RGD) peptides of varying lengths as structural probes of the platelet glycoprotein IIb/IIIa receptor. Blood 1992; 79: 117-28. 25 Male R, Vannier WE, Baldeschwieler JD. Phagocytosis of liposomes by human platelets. Proc Natl Acad Sci U S A 1992; 89: 9191-5.
